

| RECOMMENDATION SNAPSHOT |             |                |        |                  |
|-------------------------|-------------|----------------|--------|------------------|
| *CMP                    | MCap (Rsbn) | Recommendation | Target | Potential Upside |
| Rs1487                  | 24.7        | Buy            | Rs2500 | 68%              |

\*as on 27th May, 2026

### About the Company:

The Bharat Rasayan Limited (BRL), the flagship company of the Bharat group, was incorporated in 1985. The company is engaged in the manufacturing of technical grade pesticides, which in turn is used from manufacturing of formulations for agrochemical industry. While the corporate headquarters are in New Delhi, the manufacturing units are located in Bahadurgarh and Rohtak (Haryana), Dahej (Gujarat), Kathua (J&K) and Kala Amb (H.P). Currently, BRL has two manufacturing plants equipped with state-of-art process systems located in the states of Haryana and Gujarat. The Gupta family, Mr. S.N. Gupta, Mr. M.P. Gupta and Mr. R.P. Gupta are the promoters of the company.

### Results: Quick Glance:

- The net sales for the quarter under review grew flat by 0.5% to Rs3,080mn as compared to Rs3,065mn in Q4FY25
- The Ebitda margins for the quarter under review stood at 16.3% as against 13.1% in Q4FY25
- The net profit (considering share of P&L of JV) came in at Rs382mn as against Rs251mn in Q4FY25
- The EPS for the quarter under review stood at Rs22.95 as compared to Rs60.48 in the corresponding period last year
- For the full year, the revenues have reported a growth of 5.9% on a y-o-y basis. The Ebitda margins stood at 16.0% as compared to 14.9% in FY25. Net profit reported growth of 3.4% on a y-o-y basis. The EPS for the year stood at Rs87.67 as compared to Rs84.79 in FY25
- The Board has recommended a final dividend of Rs0.50 per share of FV of Rs5 each

### Financials:

| Performance (Q4&FY26)  |        |        |         |        |         |       |       |         |       |
|------------------------|--------|--------|---------|--------|---------|-------|-------|---------|-------|
| Q4&FY26 Result (Rs mn) | Mar-26 | Mar-25 | y-o-y   | Dec-25 | q-o-q   | FY26  | FY25  | y-o-y   | FY27E |
| Total Revenue          | 3080   | 3065   | 0.5%    | 2705   | 13.9%   | 12418 | 11730 | 5.9%    | 13288 |
| EBITDA                 | 501    | 402    | 24.7%   | 428    | 17.2%   | 1991  | 1749  | 13.9%   | 2126  |
| Other Income           | 156    | 61     | -       | 95     | 64.2%   | 412   | 260   | 58.4%   | 504   |
| Interest               | 9      | 12     | (23.1%) | 14     | (33.1%) | 46    | 47    | (2.8%)  | 51    |
| Depreciation           | 68     | 72     | (5.6%)  | 67     | 1.2%    | 264   | 270   | (2.3%)  | 286   |
| Exceptional Items      | (55)   | -      | -       | 15     | -       | (188) | -     | -       | 0     |
| Share of Profit        | (10)   | (33)   | -       | 60     | -       | 28    | 158   | (82.3%) | 42    |
| Tax                    | 133    | 94     | 41.2%   | 117    | 14.3%   | 477   | 441   | 8.1%    | 585   |
| Net Profit             | 382    | 251    | 51.8%   | 400    | (4.7%)  | 1457  | 1409  | 3.4%    | 1750  |

**Outlook and Recommendations:** BRL has been a **consistent performer** with modest topline growth but the margins continue to expand. It continues to be the strongest player in the industry; and this is despite a weak agrochemical cycle. The company has been able to survive the downcycle comfortably with low refinancing risk and strong supplier credibility while trying to capture the distressed opportunities with a strong cash war chest. On the **working capital**, the company continues to show better collection ability, with slightly higher inventory which is kept as a backup for supply chain disruptions, if any. Furthermore, the inventory pile up is also higher attributed to the upcoming seasonal sales. The **JV** continues to report forex losses which cannot be mitigated to a larger extent; while the company continues to remain relatively conservative in disclosures to the investor community. There are a number of products which are currently under development mode for the JV, which are initially anticipated to be supplied by BRL and then after 4-6 quarters supplied via the JV. The company continues to cater to some of the **marquee customers** in the industry like Nissan, Mitsui and Sumitomo. In addition to this, the other partnership with Mitsui & Co. and Nippon Soda Co. Ltd (under the JV Bharat Certis AgriScience Ltd) is anticipated to deliver stable revenues for the crop protection solutions in the domestic as well as the international market. The main focus of the company is to scout for export opportunities in Europe, America and Japan; BRL is also looking at adding more Japanese products to its portfolio which can be seen in the exports data of the last 2-3 quarters.

**Outlook and Recommendations (contd.):**

As mentioned in our previous notes as well, BRL continues to focus on R&D, securing more registrations for good quality products while concentrating only on the bottom line; many of these new additions are expected to be high value, but low volume products. BRL continues to focus on better chemistries/better products for its key customers from the Japanese counterparts. The company is looking for opportunities in both generic as well as patented products which can also lead to margin expansion in quarters to come. The company is currently witnessing a rejig at the **higher Management** levels which invites succession transition risks as well. Skills of the new members, of the family run business, will need time to strategize and fructify the operational responsibilities/strength. BRL continues to grow as one of the high-quality technical agrochemical manufacturers in India with strong process chemistry capability, exceptionally good balance sheet strength, superior return profile with solid operational skills. It is a good compounder of wealth owing to a number of factors which support growth including the new molecule pipeline, scaleup of the export business scale-up, backward integration, monetisation of the capacity monetization, gains from China+1 strategy, better product mix, stronger pricing power as well as the management succession quality. We continue to maintain our target price of Rs2500.

## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

## Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at the discretion of the clients to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai-400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500

### Compliance Officer:

Ms. Mamatha Poojari,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500

### Grievance Officer:

Email: grievancecell@progressiveshares.com